Proteomics in Morbid Obesity After Bariatric Surgery (PROTOBESE)

January 29, 2014 updated by: Geltrude Mingrone, Catholic University of the Sacred Heart

Identification of a Novel Factor(s) of Importance to Insulin Resistance -Repeated Blood Sampling Before and After Biliopancreatic Diversion

Glycemic control is rapidly restored in patients with insulin resistance after bariatric surgery, in particular after the mal-absorptive one (i.e. Bilio-pancreatic diversion, BPD). To evaluate the mechanisms allowing restoration of insulin sensitivity after BPD the investigators aimed at identifying by using a proteomic approach plasma proteins or peptides that may be involved in the remarkably fast and explicit restoration of insulin sensitivity. In addition to the unbiased proteomics approach, a selection of recognized markers for metabolic control will be measured. These efforts all aim at an increased understanding of how insulin sensitivity is regulated and may provide novel ideas of how to treat insulin resistance and type 2-diabetes.

Study Overview

Status

Completed

Detailed Description

Study design The study is designed as a single-centre, observational study. The patients will undergo routine analyses usually performed before and after biliopancreatic diversion surgery (BPD), independently of the participation to this specific protocol with the only exception of meal test. Twenty morbidly obese male subjects scheduled for BPD for will be included in the study.

The inclusion and exclusion criteria are set as to create a sufficiently homogenous study population.

As outlined in the study flow chart subjects will be studied and blood samples collected at 3 weeks (+/- 1 week) and 4 days (+/- 1 day) before the day of BPD surgery (baseline-1 and baseline-2), at the day of surgery (day 0), every second day after surgery during the first week (immediate post surgery) as well as two and four weeks after surgery (post surgery-1 and post surgery-2). A deviation of +/- 2 days is allowed for the post surgery-1 and post surgery-2 visits.

All fasting samples are obtained in the morning after an overnight fast (12 h). Immediate post surgery (fasting) samples will be collected after 12 h rest from parenteral nutrition from the arm not used for nutritional substitution during the first 4 days after surgery (when parenteral nutrition is given). The immediate post surgery (fasting) samples obtained from day 5 and forward after surgery, when subjects have started to eat, will be obtained in the morning after an overnight fast (12 h). Nutrient stimulation samples will be obtained at baseline-1 and 2 and post surgery-1 and 2 after intake of a test meal. A complete list of all procedures for each visit is provided in Table 1 and an overview of all planned blood samples, including volumes and purpose is provided in Table 2. Motivations for the collection of various samples are provided under section 10.3.1 "Proteomics analysis, experimental design issues".

In case of discontinuation, additional subjects should be enrolled such that a complete set of samples from no less than 20 subjects can be obtained.

Target subject population Inclusion criteria

  • Morbidly obese male with a BMI >40 kg/m2 who, for their obesity disease, are eligible for bariatric surgery and have accepted to undergo BPD
  • Confirmed insulin resistance; fasting serum insulin level > 60 pmol/L
  • Age 25-55 years
  • Weight stable for at least 6 months before the study (+/- 5 kg within the previous 6 months)
  • Stable medication
  • Provision of informed consent, statistical analysis, and publications of obtained results Exclusion criteria
  • Patients not eligible for BPD
  • Incapacity to give a valid informed consent or unwilling to give the consent
  • Patients eligible for BPD, but with:

    • Type 2-diabetes mellitus
    • Significant illness within the two weeks preceding surgery, as judged by the physician.
    • Obvious infection (bacteria, virus etc)
    • Major cardiovascular disease
    • Major gastrointestinal, respiratory, or any hormonal disorders
    • Medication affecting lipid metabolism within 3 months of the study
    • History of drug addiction and/or alcohol use
    • Suspected or confirmed poor compliance
    • Exercise +/-3 times a week
    • Blood donation within 12 weeks preceding screening visit

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rome, Italy, 00168
        • Day Hospital of Metabolic Diseases, Catholic University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Sampling Method

Non-Probability Sample

Study Population

Twenty male, morbidly obese subjects

Description

Inclusion Criteria:

  • Morbidly obese male with a BMI >40 kg/m2 who, for their obesity disease, are eligible for bariatric surgery and have accepted to undergo BPD
  • Confirmed insulin resistance; fasting serum insulin level > 60 pmol/L
  • Age 25-55 years
  • Weight stable for at least 6 months before the study (+/- 5 kg within the previous 6 months)
  • Stable medication
  • Provision of informed consent, statistical analysis, and publications of obtained results

Exclusion Criteria:

  • Patients not eligible for BPD
  • Incapacity to give a valid informed consent or unwilling to give the consent
  • Patients eligible for BPD, but with:

    • Type 2-diabetes mellitus
    • Significant illness within the two weeks preceding surgery, as judged by the physician.
    • Obvious infection (bacteria, virus etc)
    • Major cardiovascular disease
    • Major gastrointestinal, respiratory, or any hormonal disorders
    • Medication affecting lipid metabolism within 3 months of the study
    • History of drug addiction and/or alcohol use
    • Suspected or confirmed poor compliance
    • Exercise +/-3 times a week
    • Blood donation within 12 weeks preceding screening visit

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Bilio-pancreatic diversion
Each subject is own control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proteomics
Time Frame: 2 years
used to identify plasma proteins or peptides that may be involved in the remarkably fast and explicit restoration of insulin sensitivity seen in morbidly obese patients with insulin resistance shortly after gastric bypass surgery by BPD.
2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Insulin sensitivity and secretion and incretins
Time Frame: 2 years
Selection of recognized markers for metabolic control. Insulin secretion is measured by C-peptide deconvolution and insulin sensitivity by minimal modelling of glucose-insulin after a meal. Increatins will be measured too.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Geltrude Mingrone, Professor, Catholic University of Rome

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2009

Primary Completion (Actual)

January 1, 2011

Study Completion (Actual)

July 1, 2012

Study Registration Dates

First Submitted

June 11, 2010

First Submitted That Met QC Criteria

June 28, 2010

First Posted (Estimate)

June 29, 2010

Study Record Updates

Last Update Posted (Estimate)

January 30, 2014

Last Update Submitted That Met QC Criteria

January 29, 2014

Last Verified

January 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Insulin Resistance

Subscribe